St John's wort
St John's wort (Hypericum perforatum) is a herbal preparation used by some patients for mild depressive symptoms; it is not recommended by NICE for prescribing because of variable potency and significant interactions.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Its antidepressant activity is attributed to constituents such as hyperforin and hypericin, which are thought to inhibit reuptake of several monoamines, though the precise mechanism is not fully defined.
Prescribing in practice
- It is a potent inducer of CYP3A4 and P-glycoprotein and can reduce the effectiveness of many medicines, including combined hormonal contraceptives, ciclosporin, anticoagulants and some antiretrovirals and anticonvulsants.
- Combined with serotonergic antidepressants it may precipitate serotonin syndrome.
- Preparations vary widely in active content, so effects and interactions are unpredictable and patients may not disclose its use.
Monitoring
Review all concurrent medicines for loss of efficacy when St John's wort is started or stopped, and watch for serotonergic effects with other antidepressants.
Counselling the patient
- Always tell your doctor or pharmacist if you are taking St John's wort, as it interacts with many prescribed medicines.
- It can make hormonal contraception less reliable, so discuss alternative contraception.
- Do not start or stop it without advice if you take other regular medicines.
Evidence & guidelines
MHRA and NICE highlight the clinically important enzyme-inducing interactions of St John's wort, and NICE does not recommend its prescribing for depression.
Reference: MHRA; NICE NG222; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185